125 related articles for article (PubMed ID: 20591737)
1. New lessons about old molecules: how type I interferons shape Th1/Th17-mediated autoimmunity in the CNS.
Prinz M; Kalinke U
Trends Mol Med; 2010 Aug; 16(8):379-86. PubMed ID: 20591737
[TBL] [Abstract][Full Text] [Related]
2. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system.
Prinz M; Schmidt H; Mildner A; Knobeloch KP; Hanisch UK; Raasch J; Merkler D; Detje C; Gutcher I; Mages J; Lang R; Martin R; Gold R; Becher B; Brück W; Kalinke U
Immunity; 2008 May; 28(5):675-86. PubMed ID: 18424188
[TBL] [Abstract][Full Text] [Related]
3. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F
Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668
[TBL] [Abstract][Full Text] [Related]
4. Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis.
Murphy AC; Lalor SJ; Lynch MA; Mills KH
Brain Behav Immun; 2010 May; 24(4):641-51. PubMed ID: 20138983
[TBL] [Abstract][Full Text] [Related]
5. Immunological basis for the development of tissue inflammation and organ-specific autoimmunity in animal models of multiple sclerosis.
Korn T; Mitsdoerffer M; Kuchroo VK
Results Probl Cell Differ; 2010; 51():43-74. PubMed ID: 19513635
[TBL] [Abstract][Full Text] [Related]
6. Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients.
Pentón-Rol G; Cervantes-Llanos M; Cabrera-Gómez JA; Alonso-Ramírez R; Valenzuela-Silva C; Rodríguez-Lara R; Montero-Casimiro E; Bello-Rivero I; López-Saura P
Int Immunopharmacol; 2008 Jun; 8(6):881-6. PubMed ID: 18442793
[TBL] [Abstract][Full Text] [Related]
7. Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis.
Zhang X; Markovic-Plese S
Clin Neurol Neurosurg; 2010 Sep; 112(7):641-5. PubMed ID: 20570038
[TBL] [Abstract][Full Text] [Related]
8. T-cells in multiple sclerosis.
Severson C; Hafler DA
Results Probl Cell Differ; 2010; 51():75-98. PubMed ID: 19582415
[TBL] [Abstract][Full Text] [Related]
9. Interferon-beta inhibits Th1 responses at the dendritic cell level. Relevance to multiple sclerosis.
Bartholomé EJ; Willems F; Crusiaux A; Thielemans K; Schandené L; Goldman M
Acta Neurol Belg; 1999 Mar; 99(1):44-52. PubMed ID: 10218092
[TBL] [Abstract][Full Text] [Related]
10. Preferential recruitment of interferon-gamma-expressing TH17 cells in multiple sclerosis.
Kebir H; Ifergan I; Alvarez JI; Bernard M; Poirier J; Arbour N; Duquette P; Prat A
Ann Neurol; 2009 Sep; 66(3):390-402. PubMed ID: 19810097
[TBL] [Abstract][Full Text] [Related]
11. IFN-beta inhibits human Th17 cell differentiation.
Ramgolam VS; Sha Y; Jin J; Zhang X; Markovic-Plese S
J Immunol; 2009 Oct; 183(8):5418-27. PubMed ID: 19783688
[TBL] [Abstract][Full Text] [Related]
12. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.
Marckmann S; Wiesemann E; Hilse R; Trebst C; Stangel M; Windhagen A
Clin Exp Immunol; 2004 Dec; 138(3):499-506. PubMed ID: 15544628
[TBL] [Abstract][Full Text] [Related]
13. Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation.
Gigli G; Caielli S; Cutuli D; Falcone M
Immunology; 2007 Nov; 122(3):409-17. PubMed ID: 17617156
[TBL] [Abstract][Full Text] [Related]
14. Multiple sclerosis: a complicated picture of autoimmunity.
McFarland HF; Martin R
Nat Immunol; 2007 Sep; 8(9):913-9. PubMed ID: 17712344
[TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma and interleukin-4-producing T cells in peripheral blood of multiple sclerosis patients.
Franciotta D; Zardini E; Bergamaschi R; Andreoni L; Cosi V
Eur Cytokine Netw; 2000 Dec; 11(4):677-81. PubMed ID: 11125313
[TBL] [Abstract][Full Text] [Related]
16. Human interferons alpha, beta and omega.
Bekisz J; Schmeisser H; Hernandez J; Goldman ND; Zoon KC
Growth Factors; 2004 Dec; 22(4):243-51. PubMed ID: 15621727
[TBL] [Abstract][Full Text] [Related]
17. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.
Rep MH; van Oosten BW; Roos MT; Adèr HJ; Polman CH; van Lier RA
J Clin Invest; 1997 May; 99(9):2225-31. PubMed ID: 9151795
[TBL] [Abstract][Full Text] [Related]
18. Type I interferon response in the central nervous system.
Paul S; Ricour C; Sommereyns C; Sorgeloos F; Michiels T
Biochimie; 2007; 89(6-7):770-8. PubMed ID: 17408841
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic strategy for multiple sclerosis targeting NK and NKT cells].
Yamamura T
Rinsho Shinkeigaku; 2001 Dec; 41(12):1162-4. PubMed ID: 12235827
[TBL] [Abstract][Full Text] [Related]
20. Shifting therapeutic attention in MS to osteopontin, type 1 and type 2 IFN.
Steinman L
Eur J Immunol; 2009 Sep; 39(9):2358-60. PubMed ID: 19681057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
